OS Therapies Publishes Four Articles on OST-HER2 and Osteosarcoma, Signaling Clinical Progress
Decision brief
Answer first · skim in under a minute
OS Therapies has announced the publication of four articles focusing on its lead asset OST-HER2 and osteosarcoma in Drug Discovery World. This news coincides with the company's upcoming presentation of Phase 2b clinical trial data at the ASCO Annual Meeting and its plans for a BLA filing.
OS Therapies tied four Drug Discovery World pieces on OST-HER2 and osteosarcoma to Phase 2b data from NCT04974008 and a planned 2026 biologics path. For rare-tumor BD teams, the signal is regulatory narrative plus survival readouts, not a new approved label.
Contents10 sections
Key Takeaways
- OST-HER2 is studied in NCT04974008 as OST31-164 maintenance after fully resected lung-metastatic osteosarcoma in ages 12–39.
- Company-reported 12-month EFS was 33% versus 20% historical control in January 2025 (p=0.0158), later updated to 35% of 40 patients (p=0.0194).
- Interim overall survival trends favored OST-HER2 at one and two years versus historical controls, but the three-year OS secondary endpoint is still maturing.
- FDA and EMA designations support an accelerated-review story; no FDA approval for human osteosarcoma has been granted.
What did OS Therapies publish about OST-HER2?
The company said four Drug Discovery World articles on OST-HER2 and osteosarcoma appeared between December 2025 and May 2026. Titles span treatment outlook, canine comparative oncology, regulatory science, and accelerated approval arguments.
Those pieces are commentary and scientific framing. They do not replace peer-reviewed Phase 3 proof. Investors should read them beside the registry protocol and the company efficacy releases.
How is NCT04974008 designed for OST-HER2?
According to ClinicalTrials.gov NCT04974008, OST31-164 is an open-label Phase 2 maintenance study after complete resection of pulmonary recurrent osteosarcoma.
- Planned enrollment was up to 45 patients; the registry lists 39 participants.
- Dosing is 1×109 CFU every 3 weeks for 48 weeks.
- Primary outcome is 12-month event-free survival versus historical controls.
- Secondary outcomes include three-year overall survival and treatment-emergent adverse events.
- Status is active, not recruiting, with primary completion listed as 21 September 2023.
NCI’s osteosarcoma PDQ notes that metastatic and recurrent disease still drives most deaths, which is why a post-resection maintenance strategy matters clinically (Cancer.gov osteosarcoma PDQ).
What efficacy numbers has the company disclosed?
In a 15 January 2025 Business Wire release, OS Therapies said the Phase 2b primary endpoint was met.
- 12-month EFS: 33% with OST-HER2 versus 20% historical control (p=0.0158).
- One-year OS: 91% versus 80% historical control (p=0.0700).
- Two-year OS: 61% versus 40% historical control (p=0.0576).
- All patients who hit the 12-month EFS mark remained alive at that update.
A 30 June 2025 Business Wire update presented at MIB Agents Factor cited 35% (14 of 40) one-year EFS versus 20% (p=0.0194). Thirteen of 40 patients had serious adverse events; seven had grade 3 treatment-associated events; none had grade 4 or 5 treatment-associated events in that cut.
What regulatory path is OST-HER2 on in 2026?
Company releases state FDA Rare Pediatric Disease, Fast Track, and Orphan designations, plus EMA Orphan, Fast Track, and ATMP status. OS Therapies has described End of Phase 2 and Type D FDA interactions and a goal of a Biologics License Application under accelerated approval.
A Priority Review Voucher would become relevant only after a rare pediatric disease approval. Sale prices for other vouchers are not a guarantee of future proceeds for OSTX.
For EU readers, Conditional Marketing Authorisation talk is company guidance, not an EMA decision. Watch official EMA and FDA notices rather than investor decks alone.
Why osteosarcoma remains a high unmet need
Osteosarcoma is the most common primary bone cancer in adolescents and young adults. Standard care still centers on surgery plus multi-agent chemotherapy.
The Cancer.gov PDQ stresses that outcomes worsen sharply once disease recurs in the lung. Few new systemic options have changed that pattern in decades. That gap is why a Listeria-vectored HER2 vaccine draws BD attention despite single-arm design risk.
What remains unproven for OST-HER2?
The Phase 2b study is single-arm and uses historical controls. That design can bias EFS and OS comparisons. Independent peer-reviewed full data packages and FDA review still sit ahead of any label claim.
Three-year overall survival is not final in public company cuts. Mechanism claims about antigen presentation and NK or T-cell activation need durable clinical correlation. USDA conditional canine approval does not prove human benefit.
Delete any assumption that four DDW articles equal regulatory approval. They support narrative; they do not replace a completed BLA review.
Related NovaPharma coverage
- FDA voucher program pause and rare disease policy
- Synthetic real-world data in oncology trial decisions
- Regulatory round-up: EMA opinions and FDA approvals
Frequently Asked Questions
What is OST-HER2 and which trial is testing it?
OST-HER2 (OST31-164) is a Listeria-based HER2-targeted immunotherapy. The Phase 2 study NCT04974008 tests maintenance dosing after resection of pulmonary recurrent osteosarcoma in patients aged 12 to 39 years.
What Phase 2b efficacy has OS Therapies reported for OST-HER2?
In January 2025, OS Therapies said 12-month event-free survival was 33% versus a 20% historical control (p=0.0158). A June 2025 update cited 35% (14 of 40) one-year EFS versus 20% (p=0.0194).
Which regulatory designations does OST-HER2 hold?
Company disclosures state FDA Rare Pediatric Disease, Fast Track, and Orphan Drug designations, plus EMA Orphan, Fast Track, and ATMP status. A U.S. BLA under accelerated approval remains a company goal, not an approved label.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for OST-HER2.
Unlock full calendar →Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
